Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Enbrel 50 Mg Syringe Expected To Simplify Dosing For Psoriasis

Executive Summary

Amgen expects to receive approval by year-end for an Enbrel 50 mg pre-filled syringe that could simplify dosing of the TNF inhibitor for treatment of plaque psoriasis and other indications

You may also be interested in...



Amgen Enbrel (correction)

Amgen did not run a statistical analysis on its clinical trial at six months (1"The Pink Sheet" May 17, 2004, p. 33). Enbrel (etanercept) received approval for psoriatic arthritis about a year before Biogen Idec Amevive (alefacept) gained approval for psoriasis...

Amgen Enbrel (correction)

Amgen did not run a statistical analysis on its clinical trial at six months (1"The Pink Sheet" May 17, 2004, p. 33). Enbrel (etanercept) received approval for psoriatic arthritis about a year before Biogen Idec Amevive (alefacept) gained approval for psoriasis...

Genentech Misses Enbrel Deadline; Amgen Contract Facility Not Ready

Genentech will not be reimbursed by Amgen for certain Enbrel manufacturing investments because Genentech's contract production line will not be ready on time, the company disclosed in its 2003 110-K filing

Related Content

UsernamePublicRestriction

Register

ID020288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel